Stonepine Capital Management LLC Buys New Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Stonepine Capital Management LLC purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 182,317 shares of the company's stock, valued at approximately $618,000. Stonepine Capital Management LLC owned approximately 0.12% of Xeris Biopharma as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in XERS. NewEdge Advisors LLC acquired a new position in Xeris Biopharma during the fourth quarter worth about $34,000. R Squared Ltd acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $42,000. Cibc World Markets Corp acquired a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $44,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the 4th quarter valued at approximately $45,000. Finally, Aquatic Capital Management LLC purchased a new position in Xeris Biopharma in the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.47% of the company's stock.

Xeris Biopharma Stock Performance

XERS stock traded down $0.08 during trading on Friday, hitting $4.81. The stock had a trading volume of 452,260 shares, compared to its average volume of 2,601,093. The stock has a market cap of $751.43 million, a price-to-earnings ratio of -10.69 and a beta of 1.10. The company's 50 day moving average price is $4.74 and its two-hundred day moving average price is $3.95. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.86 and a 1-year high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million. As a group, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on XERS. Oppenheimer upped their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. Craig Hallum raised their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Wall Street Zen cut shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Piper Sandler reiterated a "neutral" rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $6.25.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.